| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698783 | Clinical Oncology | 2011 | 7 Pages |
Abstract
We present data showing that dCRT is well tolerated and should be considered as an alternative to surgery for all patients with locally advanced oesophageal cancer, not only those with co-morbidity. Furthermore, the benefits of dCRT are not confined to carcinomas with squamous histology.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
S. Gwynne, C. Hurt, M. Evans, C. Holden, L. Vout, T. Crosby,